STOCK TITAN

LumiraDx Limited - LMDX STOCK NEWS

Welcome to our dedicated news page for LumiraDx (Ticker: LMDX), a resource for investors and traders seeking the latest updates and insights on LumiraDx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LumiraDx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LumiraDx's position in the market.

Rhea-AI Summary
LumiraDx Limited (Nasdaq: LMDX) will be suspended from trading on January 9, 2024, due to failure to maintain compliance with Nasdaq’s listing standards. The company's subsidiaries have appointed joint administrators and signed an agreement to sell certain companies to Roche.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
LumiraDx Limited (Nasdaq: LMDX) announced the appointment of joint administrators for two subsidiaries and the sale of certain companies to Roche for a purchase price of USD 295 million. The completion of the transaction is expected to close by mid-2024, subject to regulatory approvals. The sale proceeds will be used to repay outstanding amounts under the senior secured loan agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
LumiraDx Limited received a notice from Nasdaq stating that its securities are subject to delisting due to non-compliance with the Minimum Bid Price Requirement. The Company intends to appeal the delisting determination and is working on a plan to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
LumiraDx announces collaboration with AstraZeneca and Everton in the Community to set up England's first community-based heart and lung screening hub
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary
LumiraDx announces Q2 2023 financial results, submits FDA applications for COVID tests, and ships new instruments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Summary
LumiraDx Limited (Nasdaq: LMDX) will release its second quarter financial results on August 24, 2023. The company will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
Rhea-AI Summary
LumiraDx has signed a distribution agreement with Axonlab, granting exclusive distribution rights in Switzerland and additional non-exclusive distribution rights in Germany. Axonlab will sell LumiraDx's Point of Care testing solution, expanding the reach of the LumiraDx Platform. The agreement combines Axonlab's commercial network with LumiraDx's rapid diagnostic system, allowing more customers and patients to benefit from the product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
-
Rhea-AI Summary
LumiraDx submits a traditional 510(k) Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.63%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.57%
Tags
covid-19
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
LumiraDx Limited

Nasdaq:LMDX

LMDX Rankings

LMDX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing

About LMDX

healthcare organizations continue to wrestle with avoidable costs, preventable errors, and operational inefficiency, all while aspiring to improve their consumer experience, outcomes, and bottom line. meanwhile our economies continue to be challenged by rising healthcare costs attributable to fragmented care and long term conditions, especially diabetes, heart failure, copd, and their co-morbidities. common approaches to address these challenges – rip-and-replace information systems, deploy siloed programs that hope to “manage” high-risk patients, use minimally interconnected systems to coordinate care – have proven exorbitantly expensive, unduly cumbersome, financially unsustainable, and eventually inadequate to achieve desired benefits. lumiradx offers proven solutions to directly address these challenges, and partners with its clients to help achieve better health care, social care, and financial outcomes, an improved consumer experience, and the agility to continue this transformat